Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1

Completed

Conditions: Breast Cancer
Prostate Cancer
Advanced Solid Tumors

Interventions: Drug: AZD5363
Drug: Enzalutamide
Drug: Fulvestrant

First Posted Date: 2017-10-16

Last Posted Date: 2023-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT03310541

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer

Completed

Conditions: Thyroid Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2017-10-03

Last Posted Date: 2023-07-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 186

Registration Number: NCT03300284

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States

and more 2 locations

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Early Phase 1

Completed

Conditions: Mantle Cell Lymphoma
Lymphoma

Interventions: Drug: BR-I (bendamustine, rituximab, ibrutinib)
Drug: VEN (Venetoclax)

First Posted Date: 2017-09-27

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT03295240

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: daratumumab
Drug: carfilzomib
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2017-09-25

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT03290950

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

Not Applicable

Completed

Conditions: Peripheral Neuropathy
Gynecologic Cancer
Breast Cancer

Interventions: Other: Wait List Control
Other: Yoga

First Posted Date: 2017-09-25

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 51

Registration Number: NCT03292328

Locations: 🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Phase 4

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Octreotide
Drug: LAR Lanreotide
Behavioral: Questionnaires

First Posted Date: 2017-09-21

Last Posted Date: 2025-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 51

Registration Number: NCT03289741

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 4 locations

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Procedure: MRI Biopsy

First Posted Date: 2017-09-20

Last Posted Date: 2024-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT03289195

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack, New York, United States

and more 4 locations

A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Other: Ketogenic Diet (KD)
Other: Standard Diet (SD)

First Posted Date: 2017-09-15

Last Posted Date: 2024-10-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT03285152

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow up), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up), Commack, New York, United States

and more 5 locations

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase 2

Active, not recruiting

Conditions: SARCOMA

Interventions: Drug: NKTR-214
Drug: Nivolumab

First Posted Date: 2017-09-13

Last Posted Date: 2025-05-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 88

Registration Number: NCT03282344

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), New York, New York, United States
🇺🇸
MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), Houston, Texas, United States

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Completed

Conditions: Multiple Myeloma

Interventions: Diagnostic Test: Oral microbiota assessment
Diagnostic Test: Comprehensive chemical gustometry
Diagnostic Test: Measurement of salivary flow
Behavioral: Surveys assessing taste disturbances

First Posted Date: 2017-09-08

Last Posted Date: 2023-07-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT03276481

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy